Literature DB >> 30478446

Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity.

Daiki Hirano1, Fumihiko Hayakawa2,3, Takahiko Yasuda4, Naoyuki Tange1, Hideyuki Yamamoto1, Yuki Kojima1, Takanobu Morishita1, Naoto Imoto5, Shinobu Tsuzuki6, Hiroyuki Mano7, Tomoki Naoe8, Hitoshi Kiyoi1.   

Abstract

MEF2D fusion genes are newly discovered recurrent gene abnormalities that are detected in approximately 5% of acute lymphoblastic leukemia cases. We previously demonstrated that the vector-driven expression of MEF2D fusion proteins was markedly stronger than that of wild-type MEF2D; however, the underlying mechanisms and significance of this expression have yet to be clarified. We herein showed that the strong expression of MEF2D fusion proteins was caused by the loss of the target site of miRNA due to gene translocation. We identified the target region of miRNA located in the coding region and selected miR-122 as a candidate of the responsible miRNA. Mutations at a putative binding site of miR-122 increased MEF2D expression, while the transfection of its miRNA mimic reduced the expression of wild-type MEF2D, but not MEF2D fusion proteins. We also found that MEF2D fusion proteins inhibited the transcriptional activity of PAX5, a B-cell differentiation regulator in a manner that depended on fusion-specific strong expression and an association with histone deacetylase 4, which may lead to the differentiation disorders of B cells. Our results provide novel insights into the mechanisms underlying leukemia development by MEF2D fusion genes and the involvement of the deregulation of miRNA-mediated repression in cancer development.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30478446     DOI: 10.1038/s41388-018-0573-9

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  2 in total

1.  The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.

Authors:  Brittany C Parker; Matti J Annala; David E Cogdell; Kirsi J Granberg; Yan Sun; Ping Ji; Xia Li; Joy Gumin; Hong Zheng; Limei Hu; Olli Yli-Harja; Hannu Haapasalo; Tapio Visakorpi; Xiuping Liu; Chang-Gong Liu; Raymond Sawaya; Gregory N Fuller; Kexin Chen; Frederick F Lang; Matti Nykter; Wei Zhang
Journal:  J Clin Invest       Date:  2013-01-09       Impact factor: 14.808

Review 2.  The role of miRNA and lncRNA in gastric cancer.

Authors:  Ning-Bo Hao; Ya-Fei He; Xiao-Qin Li; Kai Wang; Rui-Ling Wang
Journal:  Oncotarget       Date:  2017-07-12
  2 in total
  4 in total

Review 1.  Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.

Authors:  Jianfeng Li; Yuting Dai; Liang Wu; Ming Zhang; Wen Ouyang; Jinyan Huang; Saijuan Chen
Journal:  Front Med       Date:  2021-01-05       Impact factor: 4.592

Review 2.  Molecular markers in ALL: Clinical implications.

Authors:  Shunsuke Kimura; Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2020-06-07       Impact factor: 3.020

3.  MEF2D Fusions Drive Oncogenic Pre-BCR Signaling in B-ALL.

Authors:  Teresa Sadras; Markus Müschen
Journal:  Blood Cancer Discov       Date:  2020-06-22

4.  Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Shinobu Tsuzuki; Takahiko Yasuda; Shinya Kojima; Masahito Kawazu; Koshi Akahane; Takeshi Inukai; Masue Imaizumi; Takanobu Morishita; Koichi Miyamura; Toshihide Ueno; Sivasundaram Karnan; Akinobu Ota; Toshinori Hyodo; Hiroyuki Konishi; Masashi Sanada; Hirokazu Nagai; Keizo Horibe; Akihiro Tomita; Kyogo Suzuki; Hideki Muramatsu; Yoshiyuki Takahashi; Yasushi Miyazaki; Itaru Matsumura; Hitoshi Kiyoi; Yoshitaka Hosokawa; Hiroyuki Mano; Fumihiko Hayakawa
Journal:  Blood Cancer Discov       Date:  2020-06-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.